Use Able AI chat for product recommendations

Recombinant Canine CXCL8/IL-8 protein (rFc Tag)(HPLC verified)

Species

Canine

Purity

>90 %, SDS-PAGE
>90%, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg4552



Product Information

Purity >90 %, SDS-PAGE
>90%, SEC-HPLC
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Canine CXCL8 protein Ala23-Pro101 (Accession# P41324) with a rabbit IgG Fc tag at the C-terminus.
GeneID 403850
Accession P41324
PredictedSize 35.4 kDa
SDS-PAGE 36-42 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Interleukin-8 (IL-8), also known as CXCL8, is a member of the CXC chemokine family. This chemokine is secreted by a variety of cell types including monocytes/macrophages, T cells, neutrophils, fibroblasts, endothelial cells and various tumour cell lines in response to inflammatory stimuli. IL-8 has two main functions. It induces chemotaxis in target cells, primarily neutrophils but also other granulocytes, causing them to migrate to the site of infection. IL-8 also induces phagocytosis once they have arrived. This gene is thought to play a role in the pathogenesis of bronchiolitis, a common respiratory disease caused by viral infection. IL-8 is also known to be a potent promoter of angiogenesis. IL-8 has been implicated in tumour angiogenesis, metastasis and poor prognosis in breast cancer. IL-8 may represent a novel therapeutic target for estrogen-driven breast carcinogenesis and tumour progression.

References:

1.Ha H. et al. (2017) Theranostics. 7(6):1543-1588. 2.Matsushima K. et al. (2022) Cytokine. 153:155828. 3.Todorović-Raković N. et al. (2013) J Interferon Cytokine Res. 33(10):563-70. 4.Tatsuno R. et al. (2024) Cell Death Dis. 15(7):471.

||
New chat

Able™

正在加载,请稍候...